

Supplementary Table 3. Incidence of Post-Polypectomy GIB in Propensity Score-Matched Patients Treated with NOACs and Warfarin (n = 3,092)

Variable	All GIB (n = 62)			Upper GIB (n = 9)			Lower GIB (n = 53)			GIB with transfusion (n = 15)		
	Patients	GIB	Event rate (%)	Patients	GIB	Event rate (%)	Patients	GIB	Event rate (%)	Patients	GIB	Event rate (%)
Warfarin	1,546	21	1.4	102	3	2.9	1,444	18	1.2	1,546	6	0.4
NOACs	1,546	41	2.7	85	6	7.1	1,461	35	2.4	1,546	9	0.6
Apixaban	343	9	2.6	24	1	4.2	319	8	2.5	343	2	0.6
Dabigatran	421	9	2.1	27	0	0.0	394	9	2.3	421	3	0.7
Rivaroxaban	782	23	2.9	34	5	14.7	748	18	2.4	782	4	0.5
Warfarin without aspirin	1,393	12	0.9	92	3	3.3	1,301	9	0.7	1,393	4	0.3
Warfarin plus aspirin	153	9	5.9	10	0	0.0	143	9	6.3	153	2	1.3
NOACs without aspirin	1,391	34	2.4	75	5	6.7	1,316	29	2.2	1,391	8	0.6
NOACs plus aspirin	155	7	4.5	10	1	10.0	145	6	4.1	155	1	0.6
Warfarin without antiplatelet ^a	1,311	12	0.9	89	3	3.4	1,222	9	0.7	1,311	4	0.3
Warfarin plus antiplatelet ^a	235	9	3.8	13	0	0.0	222	9	4.1	235	2	0.9
NOACs without antiplatelet ^a	1,336	29	2.2	71	4	5.6	1,265	25	2.0	1,336	8	0.6
NOACs plus antiplatelet ^a	210	12	5.7	14	2	14.3	196	10	5.1	210	1	0.5
Warfarin without PPI	1,261	12	1.0	72	1	1.4	1,189	11	0.9	1,261	4	0.3
Warfarin plus PPI	285	9	3.2	30	2	6.7	255	7	2.7	285	2	0.7
NOACs without PPI	1,256	33	2.6	51	6	11.8	1,205	27	2.2	1,256	8	0.6
NOACs plus PPI	290	8	2.8	34	0	0.0	256	8	3.1	290	1	0.3

^aAntiplatelets include clopidogrel, ticagrelor and prasugrel. GIB, gastrointestinal bleeding; NOACs, non-vitamin K antagonist oral anticoagulants; PPI, proton pump inhibitor.